Related Experiment Videos
Thallium SPECT-based stereotactic targeting for brain tumor biopsies. A technical note
S Hemm1, Nathalie Vayssiere, Michel Zanca
1Department of Neurosurgery (Research Group on Movement Disorders), University Hospital, Montpellier, France.
Stereotactic and Functional Neurosurgery
|August 12, 2004
Summary
This study developed a new method using stereotactic 201Tl-SPECT imaging to improve brain tumor biopsy accuracy. The validated technique precisely identifies the most metabolically active tumor area for better surgical planning and diagnosis.
Area of Science:
- Neurosurgery
- Nuclear Medicine
- Medical Imaging
Background:
- Stereotactic (ST) MR or CT imaging is standard for brain tumor biopsy planning.
- Improving target selection reliability in ST biopsies is crucial for accurate diagnosis and treatment.
Purpose of the Study:
- To design and validate a methodology for enhanced stereotactic target selection in brain tumor biopsies.
- To integrate stereotactic 201Tl-SPECT (thallium-201 single-photon emission computed tomography) data into surgical planning.
Main Methods:
- Adapted a Philips gamma camera system for ST acquisitions using a patient pallet and headholder.
- Developed custom software for ST target determination based on the highest metabolic activity pixel in SPECT images.
- Validated system accuracy using an Elekta phantom and applied the methodology to a brain glioma biopsy.
Main Results:
- The system and software accurately identified stereotactic coordinates, with no significant geometric deformations detected.
- Phantom testing showed no significant difference between SPECT-evaluated and theoretical coordinates.
- Clinical feasibility was confirmed in one patient with a brain glioma.
Conclusions:
- The developed methodology, integrating ST 201Tl-SPECT and custom software, is feasible and accurate for brain tumor biopsy.
- This approach may improve diagnostic accuracy and patient management by targeting the most metabolically active tumor region.
- The technique holds potential for future targeted therapies delivering agents within brain tumors.